DE602006008604D1 - Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex - Google Patents

Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex

Info

Publication number
DE602006008604D1
DE602006008604D1 DE602006008604T DE602006008604T DE602006008604D1 DE 602006008604 D1 DE602006008604 D1 DE 602006008604D1 DE 602006008604 T DE602006008604 T DE 602006008604T DE 602006008604 T DE602006008604 T DE 602006008604T DE 602006008604 D1 DE602006008604 D1 DE 602006008604D1
Authority
DE
Germany
Prior art keywords
cest
magnetic resonance
resonance imaging
contrasting agents
paramagnetic complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006008604T
Other languages
English (en)
Inventor
Nicolaas P Willard
Rene T Wegh
Jeroen A Pikkemaat
Holger Gruell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips Electronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics NV filed Critical Koninklijke Philips Electronics NV
Publication of DE602006008604D1 publication Critical patent/DE602006008604D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
DE602006008604T 2005-04-26 2006-04-21 Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex Active DE602006008604D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103356 2005-04-26
PCT/IB2006/051235 WO2006114738A2 (en) 2005-04-26 2006-04-21 Mri contrast agents comprising cest active paramagnetic complex

Publications (1)

Publication Number Publication Date
DE602006008604D1 true DE602006008604D1 (de) 2009-10-01

Family

ID=37215130

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006008604T Active DE602006008604D1 (de) 2005-04-26 2006-04-21 Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex

Country Status (7)

Country Link
US (1) US8734761B2 (de)
EP (1) EP1881852B1 (de)
JP (1) JP5638752B2 (de)
CN (1) CN101166547B (de)
AT (1) ATE439866T1 (de)
DE (1) DE602006008604D1 (de)
WO (1) WO2006114738A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032705A2 (en) * 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
EP1877813B1 (de) * 2005-04-26 2013-06-19 Koninklijke Philips Electronics N.V. Mri mit kontrastmittel mit zeitmodulierter kontrastverstärkung
EP2065058A1 (de) * 2007-11-28 2009-06-03 Koninklijke Philips Electronics N.V. Nicht kugelförmige Kontrastmittel für CEST-MRI auf der Basis des magnetischen Bulk-Suszeptibilitätseffekts
US9815712B2 (en) 2008-10-03 2017-11-14 California Institute Of Technology High capacity perchlorate-selective resins from hyperbranched macromolecules
WO2010040117A2 (en) 2008-10-03 2010-04-08 California Institute Of Technology Extraction of anions from solutions and mixtures using hyperbranched macromolecules
WO2011084719A2 (en) 2009-12-17 2011-07-14 California Institute Of Technology Soluble anion exchangers from hyperbranched macromolecules
US9289505B2 (en) 2010-08-17 2016-03-22 Rutgers, The State University Of New Jersey Compositions and methods for delivering nucleic acid molecules and treating cancer
JP5802680B2 (ja) * 2010-11-26 2015-10-28 国立大学法人九州大学 常磁性を有する水溶性ハイパーブランチポリマー
CA2824063C (en) * 2011-01-09 2020-02-18 Anp Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use
US9604213B2 (en) 2012-02-13 2017-03-28 Neumodx Molecular, Inc. System and method for processing and detecting nucleic acids
CN104254595A (zh) 2012-02-13 2014-12-31 纽莫德克斯莫勒库拉尔公司 用于处理和检测核酸的微流体盒
US11648561B2 (en) 2012-02-13 2023-05-16 Neumodx Molecular, Inc. System and method for processing and detecting nucleic acids
US9637775B2 (en) 2012-02-13 2017-05-02 Neumodx Molecular, Inc. System and method for processing biological samples
US11485968B2 (en) 2012-02-13 2022-11-01 Neumodx Molecular, Inc. Microfluidic cartridge for processing and detecting nucleic acids
WO2014066376A1 (en) 2012-10-25 2014-05-01 Neumodx Molecular, Inc. Method and materials for isolation of nucleic acid materials
JP6411117B2 (ja) 2013-07-31 2018-10-24 キヤノンメディカルシステムズ株式会社 医用画像診断装置及び超音波診断装置
JP6297440B2 (ja) * 2013-07-31 2018-03-20 キヤノンメディカルシステムズ株式会社 造影剤
CN104623697B (zh) * 2015-02-08 2017-03-22 中国科学院武汉物理与数学研究所 一种基于人体生理温度响应的聚合物胶束型磁共振造影剂的制备方法
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
WO2017109111A1 (en) * 2015-12-23 2017-06-29 Bracco Imaging Spa Ratiometric pulsed cest imaging
WO2017147418A1 (en) 2016-02-24 2017-08-31 Ohio State Innovation Foundation Methods and devices for contrast agent magnetic resonance imaging
CN105963718A (zh) * 2016-04-28 2016-09-28 东华大学 一种麦芽糖修饰的钆基螯合物mr造影剂的制备方法
WO2018053460A1 (en) * 2016-09-19 2018-03-22 The Regents Of The University Of California Paramagnetic polymers
WO2018096082A1 (en) * 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CN108743977B (zh) * 2018-04-03 2021-03-02 中国科学院武汉物理与数学研究所 一种无重金属离子卟啉化合物造影剂及其在磁共振成像中的应用
CA3098492A1 (en) * 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19878A (en) 1858-04-06 Improvement in plows
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
US6746662B1 (en) 1999-02-09 2004-06-08 Board Of Regents The University Of Texas System pH sensitive MRI contrast agents
WO2000047111A1 (en) 1999-02-09 2000-08-17 Board Of Regents The University Of Texas System Ph sensitive mri contrast agents
US6963769B1 (en) 1999-04-21 2005-11-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for enhancing contrast produced by MRI
CA2425508A1 (en) * 2000-10-11 2002-04-18 John S. Pease Targeted therapeutic agents
AU2002241576A1 (en) 2000-11-20 2002-06-11 Board Of Regents University Of Texas System Paramagnetic metal ion-based macrocyclic contrast agents
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) * 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
WO2003049604A2 (en) 2001-12-13 2003-06-19 The Johns Hopkins University School Of Medicine Method for mr/nmr imaging
EP1331012A1 (de) 2002-01-29 2003-07-30 BRACCO IMAGING S.p.A. Magnetisch beeinflussbare paramagnetische Kontrastmittel für Magnetresonanzbildgebung
JP4355144B2 (ja) 2003-01-21 2009-10-28 学校法人日本大学 新規含窒素環状化合物
EP1466629A1 (de) * 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Adducte zwischen NMR Vershibungsreagenzen und Substraten mit austauschbaren Protonen für die "CEST" Anwendung
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
WO2006032705A2 (en) * 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging

Also Published As

Publication number Publication date
US8734761B2 (en) 2014-05-27
EP1881852A2 (de) 2008-01-30
US20080193384A1 (en) 2008-08-14
EP1881852B1 (de) 2009-08-19
CN101166547A (zh) 2008-04-23
WO2006114738A3 (en) 2007-06-21
JP5638752B2 (ja) 2014-12-10
ATE439866T1 (de) 2009-09-15
CN101166547B (zh) 2013-02-06
WO2006114738A2 (en) 2006-11-02
JP2008539223A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
DE602006008604D1 (de) Kontrastmittel für die magnetresonanzbildgebung mit cest-aktivem paramagnetischem komplex
Witney et al. Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C] pyruvate and [1, 4-13C2] fumarate
Singh et al. On B1 inhomogeneity correction of in vivo human brain glutamate chemical exchange saturation transfer contrast at 7T
Chen et al. Evaluations of tumor acidosis within in vivo tumor models using parametric maps generated with acidoCEST MRI
Imai et al. Effects on rat testis of 1.95-GHz W-CDMA for IMT-2000 cellular phones
DE602005016784D1 (de) Kontrastmittel für die magnetresonanztomographie
Huang et al. Characteristics of magnetic labeling on liver tumors with anti-alpha-fetoprotein-mediated Fe3O4 magnetic nanoparticles
CN107205612B (zh) 位置检测系统以及位置检测方法
Park et al. p21WAF1 is required for interleukin-16-induced migration and invasion of vascular smooth muscle cells via the p38MAPK/Sp-1/MMP-9 pathway
Lim et al. MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy
Demirkesen et al. The expression of IgM is helpful in the differentiation of primary cutaneous diffuse large B cell lymphoma and follicle center lymphoma
Kuwahata et al. Development of magnetic probe for sentinel lymph node detection in laparoscopic navigation for gastric cancer patients
Tain et al. Improving the detection specificity of endogenous MRI for reactive oxygen species (ROS)
WO2006067692A3 (en) Arrangement and method for determining the spatial distribution of magnetic particles
Sillerud Quantitative [Fe] MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels
ATE421145T1 (de) Aktive abschirmung für eine schaltung mit magnetisch empfindlichen materialien
Liu et al. MagA expression attenuates iron export activity in undifferentiated multipotent P19 cells
DE502005005641D1 (de) Testobjekt für Kernspintomographen
Garanger et al. A DNA-binding Gd chelate for the detection of cell death by MRI
Vourganti et al. MR/US fusion technology: what makes it tick?
Djordjevic et al. Biomedical applications
WO2007087311A3 (en) Systems and methods for determining a cardiovascular parameter using temperature sensitive magnetic resonance imaging
Alt et al. Active microcoil tracking in the lungs using a semisolid rubber as signal source
Vahala et al. A study of the use of Overhauser enhancement to assist with needle and catheter placement during interventional MRI
Aktan et al. Prostate central zone characteristics with multiparametric prostate MRI

Legal Events

Date Code Title Description
8364 No opposition during term of opposition